Cover Image
Read Now

Off-label use of intravenous immunoglobulin for solid organ transplant rejection a review of clinical effectiveness

Intravenous immunoglobulin (IVIG) has been identified as a potentially beneficial therapy for patients experiencing solid organ transplant rejection. The purpose of this report is to provide a synthesis of the available evidence on the clinical effectiveness of off-label use of IVIG for solid organ...

Full description

Bibliographic Details
Main Authors: Khangura, Sara, Visintini, Sarah (Author)
Corporate Authors: Canadian Agency for Drugs and Technologies in Health, Canadian Agency for Drugs and Technologies in Health Rapid Response Service
Format: eBook
Language:English
Published: Ottawa CADTH 2018, April 30, 2018
Edition:Version 1.0
Series:CADTH rapid response report: summary with critical appraisal
Subjects:
Graft Rejection / Prevention & Control
Graft Rejection / Drug Therapy
Off-label Use
Treatment Outcome
Immunoglobulins, Intravenous / Therapeutic Use
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:Intravenous immunoglobulin (IVIG) has been identified as a potentially beneficial therapy for patients experiencing solid organ transplant rejection. The purpose of this report is to provide a synthesis of the available evidence on the clinical effectiveness of off-label use of IVIG for solid organ transplant rejection. This report is complementary to a 2017 CADTH Rapid Response, Summary of Abstracts report: "Off-Label Use of Intravenous Immunoglobulin for Solid Organ Transplant Rejection, Paraneoplastic Disorders, or Recurrent Miscarriage: Clinical Effectiveness"
Item Description:"Rapid Response Service."
Physical Description:1 PDF file (19 pages) illustration

Similar Items